Skip to main content

Advertisement

SpringerLink
Log in

The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer

  • Interventional Radiology
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Purpose

To determine the sensitivity, specificity, and complication rate of percutaneous adrenal biopsy in patients with known or suspected lung cancer.

Methods

This study was approved by the Institutional Review Board at our institution as a retrospective analysis; therefore, the need for informed consent was waived. All percutaneous adrenal biopsies performed between April 1993 and May 2019 were reviewed. 357 of 582 biopsies were performed on 343 patients with known or suspected lung cancer (M:F 164:179; mean age 66 years). The biopsy results were classified into malignant, benign, or non-diagnostic. The final diagnosis was established by pathology (biopsy and/or surgical resection) or imaging follow-up on CT for at least 12 months following the biopsy. Patients with less than 12 months follow-up were excluded (n = 44). Complications were recorded.

Results

The final diagnosis was metastatic lung cancer in 235 cases (77.8%), metastasis from an extrapulmonary primary in 2 cases (0.7%), pheochromocytoma in 2 cases (0.7%), and benign lesions in 63 cases (20.9%). Percutaneous adrenal gland biopsy had a sensitivity of 97% and specificity of 100% for lung cancer metastases. The non-diagnostic rate was 0.6%. Larger lesions were more likely to be malignant (p = 0.0000) and to be correctly classified as a lung metastasis (p = 0.025). The incidence of minor complications was 1.1%. There were no major complications.

Conclusion

Over 20% of adrenal lesions in patients with known or suspected lung cancer were not related to lung cancer. Percutaneous adrenal gland biopsy is a safe procedure, with high sensitivity and specificity for lung cancer metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chapman GS, Kumar D, Redmond J, 3rd, Munderloh SH, Gandara DR. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer. 1984;54(8):1541-3.

    Article  CAS  PubMed  Google Scholar 

  2. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery. 1991;110(6):1014-21.

    CAS  PubMed  Google Scholar 

  3. Porte HL, Roumilhac D, Graziana JP, Eraldi L, Cordonier C, Puech P, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg. 1998;65(2):331-5.

    Article  CAS  PubMed  Google Scholar 

  4. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132(6):931-9.

    Article  PubMed  Google Scholar 

  5. Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62(1):246-50.

    Article  CAS  PubMed  Google Scholar 

  6. Lenert JT, Barnett CC, Jr., Kudelka AP, Sellin RV, Gagel RF, Prieto VG, et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery. 2001;130(6):1060-7.

    Article  CAS  PubMed  Google Scholar 

  7. Frilling A, Tecklenborg K, Weber F, Kuhl H, Muller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery. 2004;136(6):1289-96.

    Article  PubMed  Google Scholar 

  8. Schwartz LH, Ginsberg MS, Burt ME, Brown KT, Getrajdman GI, Panicek DM. MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. Ann Thorac Surg. 1998;65(1):193-7.

    Article  CAS  PubMed  Google Scholar 

  9. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201-4.

    Article  CAS  PubMed  Google Scholar 

  10. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (> 10 HU) adrenal masses: does it still have a role? Radiology. 2004;231(3):711-6.

    Article  PubMed  Google Scholar 

  11. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222(3):629-33.

    Article  PubMed  Google Scholar 

  12. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217(3):798-802.

    Article  CAS  PubMed  Google Scholar 

  13. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42(12):1795-9.

    CAS  PubMed  Google Scholar 

  14. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer. 2001;3(1):59-64.

    Article  CAS  PubMed  Google Scholar 

  15. Sung YM, Lee KS, Kim BT, Choi JY, Chung MJ, Shim YM, et al. (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients. Korean J Radiol. 2008;9(1):19-28.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Porte HL, Ernst OJ, Delebecq T, Metois D, Lemaitre LG, Wurtz AJ. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer? Eur J Cardiothorac Surg. 1999;15(5):597-601.

    Article  CAS  PubMed  Google Scholar 

  17. Davidson JC, Rahim S, Hanks SE, Patel IJ, Tam AL, Walker TG, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part I: Review of Anticoagulation Agents and Clinical Considerations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30(8):1155-67.

    Article  PubMed  Google Scholar 

  18. Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30(8):1168-84 e1.

  19. Ho LM, Samei E, Mazurowski MA, Zheng Y, Allen BC, Nelson RC, et al. Can Texture Analysis Be Used to Distinguish Benign From Malignant Adrenal Nodules on Unenhanced CT, Contrast-Enhanced CT, or In-Phase and Opposed-Phase MRI? AJR Am J Roentgenol. 2019;212(3):554-61.

    Article  PubMed  Google Scholar 

  20. Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC, et al. Quality improvement guidelines for percutaneous needle biopsy. J Vasc Interv Radiol. 2010;21(7):969-75.

    Article  PubMed  Google Scholar 

  21. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

    Article  PubMed  Google Scholar 

  22. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.

  23. Oikawa A, Takahashi H, Ishikawa H, Kurishima K, Kagohashi K, Satoh H. Application of conditional probability analysis to distant metastases from lung cancer. Oncol Lett. 2012;3(3):629-34.

    Article  PubMed  Google Scholar 

  24. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618-26.

    Article  CAS  PubMed  Google Scholar 

  25. Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, 3rd, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515-22.

  26. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;89(4):880-7.

    Article  PubMed  Google Scholar 

  27. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008;26(7):1142-7.

    Article  PubMed  Google Scholar 

  28. Gao XL, Zhang KW, Tang MB, Zhang KJ, Fang LN, Liu W. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2017;24(1):1-7.

    Article  CAS  PubMed  Google Scholar 

  29. Loi M, Mazzella A, Mansuet-Lupo A, Bobbio A, Canny E, Magdeleinat P, et al. Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management. Ann Thorac Surg. 2019;107(4):1053-9.

    Article  PubMed  Google Scholar 

  30. Schieda N, Siegelman ES. Update on CT and MRI of Adrenal Nodules. AJR Am J Roentgenol. 2017;208(6):1206-17.

    Article  PubMed  Google Scholar 

  31. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol. 1998;170(3):747-52.

    Article  CAS  PubMed  Google Scholar 

  32. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175(5):1411-5.

    Article  CAS  PubMed  Google Scholar 

  33. Mayo-Smith WW, Song JH, Boland GL, Francis IR, Israel GM, Mazzaglia PJ, et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(8):1038-44.

    Article  PubMed  Google Scholar 

  34. Patel J, Davenport MS, Cohan RH, Caoili EM. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol. 2013;201(1):122-7.

    Article  PubMed  Google Scholar 

  35. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of Quantitative MRI and CT Washout Analysis for Differentiation of Adrenal Pheochromocytoma From Adrenal Adenoma. AJR Am J Roentgenol. 2016;206(6):1141-8.

    Article  PubMed  Google Scholar 

  36. Choi YA, Kim CK, Park BK, Kim B. Evaluation of adrenal metastases from renal cell carcinoma and hepatocellular carcinoma: use of delayed contrast-enhanced CT. Radiology. 2013;266(2):514-20.

    Article  PubMed  Google Scholar 

  37. Stone WZ, Wymer DC, Canales BK. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm. J Endourol. 2014;28(1):104-11.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343(4):254-61.

    Article  CAS  PubMed  Google Scholar 

  39. Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. J Biomed Biotechnol. 2012;2012:783739.

    PubMed  PubMed Central  Google Scholar 

  40. Bancos I, Tamhane S, Shah M, Delivanis DA, Alahdab F, Arlt W, et al. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R65-80.

    Article  CAS  PubMed  Google Scholar 

  41. Zhang CD, Erickson D, Levy MJ, Gleeson FC, Salomao DR, Delivanis DA, et al. Endoscopic Ultrasound-Guided Fine-Needle Aspiration in the Diagnosis of Adrenal Metastasis in a High-Risk Population. Endocr Pract. 2017;23(12):1402-7.

    Article  PubMed  Google Scholar 

  42. Lee MJ, Hahn PF, Papanicolaou N, Egglin TK, Saini S, Mueller PR, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology. 1991;179(2):415-8.

    Article  CAS  PubMed  Google Scholar 

  43. Sasaguri K, Takahashi N, Takeuchi M, Carter RE, Leibovich BC, Kawashima A. Differentiation of Benign From Metastatic Adrenal Masses in Patients With Renal Cell Carcinoma on Contrast-Enhanced CT. AJR Am J Roentgenol. 2016;207(5):1031-8.

    Article  PubMed  Google Scholar 

  44. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010;41(1):94-102.

    Article  CAS  PubMed  Google Scholar 

  45. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20(4):696-702.

    Article  PubMed  Google Scholar 

  46. Kim H, Xu X, Yoo SB, Sun PL, Jin Y, Paik JH, et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology. 2013;62(2):305-14.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Aileen O’Shea would like to acknowledge the contribution of the MGH-MacErlaine Research Scholarship from the Faculty of Radiologists, RCSI, Ireland, and Massachusetts General Hospital.

Funding

N/A.

Author information

Author notes

  1. E. McDermott and A. Kilcoyne have contributed equally to this work and are first co-authors.

Authors and Affiliations

  1. Tallaght University Hospital, Tallaght, Dublin, Ireland

    E. McDermott

  2. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA

    A. Kilcoyne, A. O’Shea, A. M. Cahalane & S. McDermott

Authors
  1. E. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Kilcoyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. O’Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. M. Cahalane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed in line with ICMJE guidelines.

Corresponding author

Correspondence to A. Kilcoyne.

Ethics declarations

Conflict of interest

All the authors declared that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McDermott, E., Kilcoyne, A., O’Shea, A. et al. The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer. Abdom Radiol 46, 1171–1178 (2021). https://doi.org/10.1007/s00261-020-02743-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-020-02743-9

Keywords

Search

Navigation